Flozins to prevent contrast-related kidney injury after coronary angiography or PCI

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective, single-centre cohort/case-control analysis of all consecutive patients who underwent coronary angiography or PCI at Collegium Medicum w Bydgoszczy between 01.01.2020 and 30.09.2025. The final analysis includes only procedures with iodine contrast volume between 50 and 500 mL and patients with both pre- and post-procedure serum creatinine measurements. The study compares occurrence of contrast-induced AKI among patients with short-term versus long-term SGLT2 inhibitor (empagliflozin or dapagliflozin) use and will analyze baseline characteristics, contrast type and volume, and serial creatinine/eGFR changes at 24, 48, and 72 hours. Results will be combined with previously published studies in a planned meta-analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* all consecutive patients who underwent PCI or coronary angiography during the study period for whom the variables required for the analysis are available

Exclusion Criteria:

* unavailability of variables required for the analysis, volume
* contrast agent volume \<50 mL or \>500 mL.

Where it's running

• Collegium Medicum w Bydgoszczy
  Bydgoszcz, Poland Recruiting

Study contacts

• Principal investigator: Jacek Kubica, Prof. — Collegium Medicum w Bydgoszczy
• Study coordinator: Piotr Niezgoda, MD, PhD
• Email: piotr.niezgoda1986@gmail.com
• Phone: +48525854023

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Aspirin 50 mg vs 100 mg with a P2Y12 inhibitor after PCI

  This trial tests whether a 50 mg daily aspirin dose, when used with a P2Y12 inhibitor after PCI, works as well as 100 mg with similar safety for people staying on DAPT for 12 months.

  Recruiting Jilin University · Changchun, Jilin · NCT07846462

• Long-term P2Y12 inhibitor monotherapy and blood clotting after angioplasty

  This trial will test whether specific P2Y12 drugs and reduced doses given alone keep platelet activity in a safe therapeutic range for people who completed initial dual antiplatelet therapy after PCI.

  Recruiting Phase 3 Cardiocentro Ticino · Lugano, Ch/ti · NCT07582835

• What affects bleeding control and how long you need to lie flat after femoral arterial sheath removal

  We will see if patient and procedure factors can predict how long ICU patients need compression and bed rest after femoral arterial sheath removal to prevent bleeding and hematoma.

  Recruiting National Taiwan University Hospital · Taipei · NCT07469397

• Doctors' and patients' preferences for PCI implantation devices

  This questionnaire tests what patients who have had PCI and the doctors who treat them prefer between drug-eluting stents and drug-coated balloons.

  Recruiting Xijing Hospital · Xi'an, Shannxi · NCT07378163

• How patients and doctors value different outcomes after coronary stent procedures

  This project asks patients who had a coronary stent (PCI) and the doctors who treat them to rate how important different possible outcomes are to see if their priorities match.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT07378137

• Temporary heart support with the iVAC 2L device during high-risk coronary procedures

  This trial will try the iVAC 2L temporary heart‑support device during high‑risk PCI to help people with severe coronary artery disease stay hemodynamically stable through the procedure.

  Recruiting National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Moscow · NCT07149714

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.